Gravis's Argent: Infrastructure sector has had a 'perfect storm'

Nationalisation debate a key issue

clock • 2 min read

Listed infrastructure has developed as an asset class in its own right over the past decade and investors have been attracted to its bond-like characteristics during a period of historically low returns on government debt.

In recent months, however, the sector has undergone what may be perceived as a perfect storm. Last September, comments at the Labour Party Conference unleashed the nationalisation debate, with Shadow Chancellor John McDonnell calling for privately financed social infrastructure assets funded through the Private Finance Initiative (PFI) to be brought back into government control.  Beyond Trump's rhetoric: Where are the infrastructureopportunities? This was followed in January by the collapse of Carillion and a National Audit Office (NAO) report into the costs and benefits of the ...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Specialist

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
European private equity yet to spend €270bn worth of capital

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Early-stage biopharma: An opportunity for strategic investment

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read
Trustpilot